Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
8.43
-0.16 (-1.86%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 101.66% from the current stock price of 8.43.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 20, 2025.
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 2 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +101.66% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +149.11% | Jan 15, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $12 | Buy → Hold | Downgrades | $17 → $12 | +42.35% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
644.04M
from 528.30M
Increased by 21.91%
Revenue Next Year
787.15M
from 644.04M
Increased by 22.22%
EPS This Year
0.12
from -0.18
EPS Next Year
0.45
from 0.12
Increased by 281.57%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 679.4M | 848.7M | 1.1B | ||
| Avg | 644.0M | 787.2M | 963.6M | ||
| Low | 600.2M | 729.2M | 851.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 31.8% | 36.4% | ||
| Avg | 21.9% | 22.2% | 22.4% | ||
| Low | 13.6% | 13.2% | 8.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.26 | 0.71 | 1.53 | ||
| Avg | 0.12 | 0.45 | 1.10 | ||
| Low | 0.02 | 0.32 | 0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 511.7% | 244.2% | ||
| Avg | - | 281.6% | 148.1% | ||
| Low | - | 177.1% | 54.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.